{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T18:17:38Z","timestamp":1786817858877,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of nonsteroidal anti-inflammatory drugs that inhibit cyclooxygenase (COX)-1 and COX-2, increases heart failure risk. It is unknown whether microsomal (m) prostaglandin (PG) E synthase (S)-1, a target downstream of COX, regulates myocardial (M) ischemia\/reperfusion (I\/R) injury, a key determinant of heart failure. Here we report that COX-1 and mPGES-1 mediate production of\u00a0substantial amounts of PGE<jats:sub>2<\/jats:sub> and confer cardiac protection in MI\/R. Deletion of <jats:italic>mPges-1<\/jats:italic> impairs cardiac microvascular perfusion and increases inflammatory cell infiltration\u00a0in mouse\u00a0MI\/R. Consistently, <jats:italic>mPges-1<\/jats:italic> deletion depresses the arteriolar dilatory response to I\/R in vivo and to acetylcholine ex vivo, and enhances leukocyte-endothelial cell interaction, which is mediated via PGE receptor-4 (EP4). Furthermore, endothelium-restricted <jats:italic>Ep4<\/jats:italic> deletion impairs microcirculation, and exacerbates MI\/R injury, irrespective of EP4 agonism. Treatment with misoprostol, a clinically available PGE analogue, improves microcirculation and reduces MI\/R injury. Thus, mPGES-1, a key microcirculation protector, constrains MI\/R injury and this beneficial effect is partially mediated via endothelial EP4.<\/jats:p>","DOI":"10.1038\/s41467-019-09492-4","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T10:04:03Z","timestamp":1556013843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["The cyclooxygenase-1\/mPGES-1\/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury"],"prefix":"10.1038","volume":"10","author":[{"given":"Liyuan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuansheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Breyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9677-7647","authenticated-orcid":false,"given":"Xuetao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Pei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garret A.","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0532-6312","authenticated-orcid":false,"given":"Miao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"9492_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"Coxib","year":"2013","unstructured":"Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769\u2013779 (2013).","journal-title":"Lancet"},{"key":"9492_CR2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMra071667","volume":"357","author":"DM Yellon","year":"2007","unstructured":"Yellon, D. M. & Hausenloy, D. J. Myocardial reperfusion injury. New Engl. J. Med. 357, 1121\u20131135 (2007).","journal-title":"New Engl. J. Med."},{"key":"9492_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1172\/JCI62874","volume":"123","author":"DJ Hausenloy","year":"2013","unstructured":"Hausenloy, D. J. & Yellon, D. M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Investig. 123, 92\u2013100 (2013).","journal-title":"J. Clin. Investig."},{"key":"9492_CR4","first-page":"935","volume":"38","author":"DJ Hausenloy","year":"2017","unstructured":"Hausenloy, D. J. et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur. Heart J. 38, 935\u2013941 (2017).","journal-title":"Eur. Heart J."},{"key":"9492_CR5","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1172\/JCI27540","volume":"116","author":"Y Cheng","year":"2006","unstructured":"Cheng, Y. et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Investig. 116, 1391\u20131399 (2006).","journal-title":"J. Clin. Investig."},{"key":"9492_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1124\/pr.59.3.1","volume":"59","author":"B Samuelsson","year":"2007","unstructured":"Samuelsson, B., Morgenstern, R. & Jakobsson, P. J. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol. Rev. 59, 207\u2013224 (2007).","journal-title":"Pharmacol. Rev."},{"key":"9492_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.prostaglandins.2015.06.002","volume":"120","author":"K Larsson","year":"2015","unstructured":"Larsson, K. & Jakobsson, P. J. Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment. Prostaglandins & Other Lipid Mediat. 120, 161\u2013165 (2015).","journal-title":"Prostaglandins & Other Lipid Mediat."},{"key":"9492_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/cpt.260","volume":"99","author":"Y Jin","year":"2016","unstructured":"Jin, Y. et al. Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib. Clin. Pharmacol. Ther. 99, 274\u2013284 (2016).","journal-title":"Clin. Pharmacol. Ther."},{"key":"9492_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/CIRCULATIONAHA.116.022308","volume":"134","author":"SY Tang","year":"2016","unstructured":"Tang, S. Y. et al. Cardiovascular consequences of prostanoid I receptor deletion in microsomal prostaglandin E synthase-1-deficient hyperlipidemic mice. Circulation 134, 328\u2013338 (2016).","journal-title":"Circulation"},{"key":"9492_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1161\/CIRCULATIONAHA.110.973685","volume":"123","author":"M Wang","year":"2011","unstructured":"Wang, M. et al. Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury. Circulation 123, 631\u2013639 (2011).","journal-title":"Circulation"},{"issue":"39","key":"9492_CR11","doi-asserted-by":"publisher","first-page":"14507","DOI":"10.1073\/pnas.0606586103","volume":"103","author":"M. Wang","year":"2006","unstructured":"Wang, M. et al. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl Acad. Sci. USA 103, 14507\u201314512 (2006).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"9492_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/ATVBAHA.118.310713","volume":"38","author":"H Hao","year":"2018","unstructured":"Hao, H. et al. Protective role of mPGES-1 (microsomal prostaglandin E synthase-1)-derived PGE2 (prostaglandin E2) and the endothelial EP4 (prostaglandin E receptor) in vascular responses to injury. Arterioscler., Thromb., Vasc. Biol. 38, 1115\u20131124 (2018).","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"key":"9492_CR13","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1161\/hc4401.098429","volume":"104","author":"MG Camitta","year":"2001","unstructured":"Camitta, M. G. et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia\/reperfusion injury but are protected by acute preconditioning. Circulation 104, 2453\u20132458 (2001).","journal-title":"Circulation"},{"key":"9492_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s003950070024","volume":"95","author":"Y Guo","year":"2000","unstructured":"Guo, Y. et al. Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res. Cardiol. 95, 479\u2013484 (2000).","journal-title":"Basic Res. Cardiol."},{"issue":"18","key":"9492_CR15","doi-asserted-by":"publisher","first-page":"10197","DOI":"10.1073\/pnas.97.18.10197","volume":"97","author":"K. Shinmura","year":"2000","unstructured":"Shinmura, K. et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc. Natl Acad. Sci. USA 97, 10197\u201310202 (2000).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"9492_CR16","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1161\/hc4301.098058","volume":"104","author":"CY Xiao","year":"2001","unstructured":"Xiao, C. Y. et al. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 104, 2210\u20132215 (2001).","journal-title":"Circulation"},{"key":"9492_CR17","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1161\/CIRCULATIONAHA.107.749739","volume":"117","author":"N Degousee","year":"2008","unstructured":"Degousee, N. et al. Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 117, 1701\u20131710 (2008).","journal-title":"Circulation"},{"key":"9492_CR18","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1161\/CIRCULATIONAHA.112.099754","volume":"125","author":"N Degousee","year":"2012","unstructured":"Degousee, N. et al. Lack of microsomal prostaglandin E(2) synthase-1 in bone marrow-derived myeloid cells impairs left ventricular function and increases mortality after acute myocardial infarction. Circulation 125, 2904\u20132913 (2012).","journal-title":"Circulation"},{"key":"9492_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.plefa.2009.05.019","volume":"81","author":"D Wu","year":"2009","unstructured":"Wu, D. et al. The effects of microsomal prostaglandin E synthase-1 deletion in acute cardiac ischemia in mice. Prostaglandins Leukot. Essent. Fat. Acids 81, 31\u201333 (2009).","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"9492_CR20","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1074\/jbc.R600038200","volume":"282","author":"Y Sugimoto","year":"2007","unstructured":"Sugimoto, Y. & Narumiya, S. Prostaglandin E receptors. J. Biol. Chem. 282, 11613\u201311617 (2007).","journal-title":"J. Biol. Chem."},{"key":"9492_CR21","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1161\/01.CIR.0000128046.54681.97","volume":"109","author":"CY Xiao","year":"2004","unstructured":"Xiao, C. Y. et al. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109, 2462\u20132468 (2004).","journal-title":"Circulation"},{"key":"9492_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1161\/HYPERTENSIONAHA.107.102590","volume":"51","author":"JY Qian","year":"2008","unstructured":"Qian, J. Y. et al. Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction. Hypertension 51, 560\u2013566 (2008).","journal-title":"Hypertension"},{"key":"9492_CR23","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1111\/j.1582-4934.2008.00430.x","volume":"13","author":"N Zidar","year":"2009","unstructured":"Zidar, N. et al. Cyclooxygenase in normal human tissues\u2014is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J. Cell. Mol. Med. 13, 3753\u20133763 (2009).","journal-title":"J. Cell. Mol. Med."},{"key":"9492_CR24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.108.814640","volume":"120","author":"A Prasad","year":"2009","unstructured":"Prasad, A., Stone, G. W., Holmes, D. R. & Gersh, B. Reperfusion injury, microvascular dysfunction, and cardioprotection: the \u201cdark side\u201d of reperfusion. Circulation 120, 2105\u20132112 (2009).","journal-title":"Circulation"},{"key":"9492_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/CIRCRESAHA.115.305364","volume":"118","author":"DD Gutterman","year":"2016","unstructured":"Gutterman, D. D. et al. The human microcirculation: regulation of flow and beyond. Circ. Res. 118, 157\u2013172 (2016).","journal-title":"Circ. Res."},{"key":"9492_CR26","first-page":"478","volume":"38","author":"AR Pries","year":"2017","unstructured":"Pries, A. R. & Reglin, B. Coronary microcirculatory pathophysiology: can we afford it to remain a black box? Eur. Heart J. 38, 478\u2013488 (2017).","journal-title":"Eur. Heart J."},{"key":"9492_CR27","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1021\/jm0700823","volume":"50","author":"MD Guerrero","year":"2007","unstructured":"Guerrero, M. D. et al. Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffold: a new class of inhibitors of prostanoid production through the selective modulation of microsomal prostaglandin E synthase-1 expression. J. Med. Chem. 50, 2176\u20132184 (2007).","journal-title":"J. Med. Chem."},{"key":"9492_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/pr.110.003517","volume":"63","author":"DF Woodward","year":"2011","unstructured":"Woodward, D. F., Jones, R. L. & Narumiya, S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 63, 471\u2013538 (2011).","journal-title":"Pharmacol. Rev."},{"key":"9492_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drudis.2016.08.003","volume":"22","author":"T Markovic","year":"2017","unstructured":"Markovic, T., Jakopin, Z., Dolenc, M. S. & Mlinaric-Rascan, I. Structural features of subtype-selective EP receptor modulators. Drug Discov. Today 22, 57\u201371 (2017).","journal-title":"Drug Discov. Today"},{"key":"9492_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1161\/01.CIR.93.2.223","volume":"93","author":"H Ito","year":"1996","unstructured":"Ito, H. et al. Clinical implications of the \u2018no reflow\u2019 phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 93, 223\u2013228 (1996).","journal-title":"Circulation"},{"key":"9492_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/CIRCINTERVENTIONS.112.000168","volume":"6","author":"TP van de Hoef","year":"2013","unstructured":"van de Hoef, T. P. et al. Impact of coronary microvascular function on long-term cardiac mortality in patients with acute ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv. 6, 207\u2013215 (2013).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"9492_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/01.RES.67.2.529","volume":"67","author":"A Koller","year":"1990","unstructured":"Koller, A. & Kaley, G. Prostaglandins mediate arteriolar dilation to increased blood flow velocity in skeletal muscle microcirculation. Circ. Res. 67, 529\u2013534 (1990).","journal-title":"Circ. Res."},{"key":"9492_CR33","first-page":"545","volume":"59","author":"P Gwozdz","year":"2007","unstructured":"Gwozdz, P., Drelicharz, L., Kozlovski, V. I. & Chlopicki, S. Prostacyclin, but not nitric oxide, is the major mediator of acetylcholine-induced vasodilatation in the isolated mouse heart. Pharmacol. Rep.: PR 59, 545\u2013552 (2007).","journal-title":"Pharmacol. Rep.: PR"},{"key":"9492_CR34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1476-5381.2011.01264.x","volume":"163","author":"N Foudi","year":"2011","unstructured":"Foudi, N. et al. Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2): implication for cardiovascular grafts. Br. J. Pharmacol. 163, 826\u2013834 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"9492_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.prostaglandins.2004.07.003","volume":"74","author":"X Norel","year":"2004","unstructured":"Norel, X., de Montpreville, V. & Brink, C. Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins & Other Lipid Mediat. 74, 101\u2013112 (2004).","journal-title":"Prostaglandins & Other Lipid Mediat."},{"issue":"22","key":"9492_CR36","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1111\/bph.13939","volume":"174","author":"Gulsev Ozen","year":"2017","unstructured":"Ozen, G. et al. Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI2: a safer alternative to COX-2 inhibition. Br. J. Pharmacol., https:\/\/doi.org\/10.1111\/bph.13939 (2017).","journal-title":"British Journal of Pharmacology"},{"key":"9492_CR37","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1126\/science.aad9903","volume":"351","author":"R Duffin","year":"2016","unstructured":"Duffin, R. et al. Prostaglandin E(2) constrains systemic inflammation through an innate lymphoid cell-IL-22 axis. Science 351, 1333\u20131338 (2016).","journal-title":"Science"},{"key":"9492_CR38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.106.647230","volume":"115","author":"L Timmers","year":"2007","unstructured":"Timmers, L. et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 115, 326\u2013332 (2007).","journal-title":"Circulation"},{"key":"9492_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/eurheartj\/ehv505","volume":"37","author":"M Schmidt","year":"2016","unstructured":"Schmidt, M. et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur. Heart J. 37, 1015\u20131023 (2016).","journal-title":"Eur. Heart J."},{"key":"9492_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.tips.2017.05.008","volume":"38","author":"T Grosser","year":"2017","unstructured":"Grosser, T., Ricciotti, E. & FitzGerald, G. A. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol. Sci. 38, 733\u2013748 (2017).","journal-title":"Trends Pharmacol. Sci."},{"key":"9492_CR41","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1161\/CIRCRESAHA.110.223925","volume":"107","author":"E Gao","year":"2010","unstructured":"Gao, E. et al. A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ. Res. 107, 1445\u20131453 (2010).","journal-title":"Circ. Res."},{"key":"9492_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1476-5381.2012.02189.x","volume":"168","author":"J Safholm","year":"2013","unstructured":"Safholm, J. et al. PGE2 maintains the tone of the guinea pig trachea through a balance between activation of contractile EP1 receptors and relaxant EP2 receptors. Br. J. Pharmacol. 168, 794\u2013806 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"9492_CR43","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1111\/j.1476-5381.2011.01495.x","volume":"164","author":"KJ af Forselles","year":"2011","unstructured":"af Forselles, K. J. et al. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist. Br. J. Pharmacol. 164, 1847\u20131856 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"9492_CR44","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/S0968-0896(01)00110-9","volume":"9","author":"H Juteau","year":"2001","unstructured":"Juteau, H. et al. Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. Bioorg. & Med. Chem. 9, 1977\u20131984 (2001).","journal-title":"Bioorg. & Med. Chem."},{"key":"9492_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/sj.bjp.0706726","volume":"148","author":"RJ Wilson","year":"2006","unstructured":"Wilson, R. J. et al. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br. J. Pharmacol. 148, 326\u2013339 (2006).","journal-title":"Br. J. Pharmacol."},{"key":"9492_CR46","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3389\/fphys.2017.00928","volume":"8","author":"HF Hao","year":"2017","unstructured":"Hao, H. F. et al. Rhynchophylline ameliorates endothelial dysfunction via Src-PI3K\/Akt-eNOS cascade in the cultured intrarenal arteries of spontaneous hypertensive rats. Front. Physiol. 8, 928 (2017).","journal-title":"Front. Physiol."},{"key":"9492_CR47","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1021\/pr501200u","volume":"14","author":"X Zhang","year":"2015","unstructured":"Zhang, X., Yang, N., Ai, D. & Zhu, Y. Systematic metabolomic analysis of eicosanoids after omega-3 polyunsaturated fatty acid supplementation by a highly specific liquid chromatography-tandem mass spectrometry-based method. J. Proteome Res. 14, 1843\u20131853 (2015).","journal-title":"J. Proteome Res."},{"key":"9492_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0076-6879(07)33003-6","volume":"433","author":"WL Song","year":"2007","unstructured":"Song, W. L., Lawson, J. A., Wang, M., Zou, H. & FitzGerald, G. A. Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC\/MS\/MS method. Methods Enzymol. 433, 51\u201372 (2007).","journal-title":"Methods Enzymol."},{"key":"9492_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1161\/CIRCULATIONAHA.111.049072","volume":"125","author":"A Galaup","year":"2012","unstructured":"Galaup, A. et al. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 125, 140\u2013149 (2012).","journal-title":"Circulation"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09492-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09492-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09492-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T22:59:31Z","timestamp":1671231571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09492-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["9492"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-09492-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"20 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1888"}}